Ipca Laboratories Limited, a pharmaceutical company, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. It offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. The company provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetology, dermatology, gastroenterology, hematology, neurology, ophthalmology, rheumatology, and urology, as well as psychiatry, probiotics, respiratory, orthopedics, oral anti diabetes drug, nutraceuticals, NSAIDs, neuropathic pain, malaria, infectious diseases, immunosuppressant, hepatoprotectives, helminthics, fever, and emollients/protectives. It also exports its products worldwide. The company was incorporated in 1949 and is based in Mumbai, India.
Stock data | 2023 | Change |
---|---|---|
Price | $16.44 | N/A |
Market Cap | $4.17B | N/A |
Shares Outstanding | 253.70M | 0.00% |
Employees | 16.17K | N/A |
Shareholder Equity | 59.15B | 6.76% |
Valuation | 2023 | Change |
---|---|---|
P/E Ratio | 0.89 | N/A |
P/S Ratio | 5.64 | N/A |
P/B Ratio | 0.07 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | 0.0010 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $740.05M | N/A |
Earnings | $57.11M | N/A |
EPS | 18.58 | N/A |
Earnings Yield | 1.13 | N/A |
Gross Margin | 0.6121 | N/A |
Operating Margin | 0.1135 | N/A |
Net income margin | 0.0772 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $1.03B | N/A |
Total Debt | $176.61M | N/A |
Cash on Hand | $259.35M | N/A |
Debt to Equity | 0.0055 | 21.92% |
Cash to Debt | $1.47 | -12.76% |
Current Ratio | $2.87 | -5.49% |